1. Scrip
  2. >>Business
  3. >>Financing

Sonoma Bio Raises $265m To Test T-regs In Autoimmune Diseases

First Indication Is RA, But IBD Is Another Opportunity

 
• By Mandy Jackson

The company will determine whether a single administration of autologous regulatory T-cells (Tregs) can reset and restore immune tolerance in autoimmune, inflammatory and neuroinflammatory diseases.

Young woman with rheumatoid arthritis deformed fingers
Sonoma Bio's T-reg therapies may offer a polypharmacy approach to treating rheumatoid arthritis and other autoimmune diseases • Source: Alamy

Sonoma Biotherapeutics revealed a $265m series B venture capital round on 4 August that will fund the first clinical trials of its autologous regulatory T-cell (Treg) therapies to test whether the company can deliver a one-time treatment with the ability to restore immune system balance in autoimmune diseases and inflammation, including neuroinflammation. Sonoma Bio’s lead Treg program is designed to treat rheumatoid arthritis, but it is also investigating Tregs for inflammatory bowel diseases.

In addition, the South San Francisco- and Seattle-based company is developing an effector T-cell (Teff)-depleting agent and plans to take that biologic, known as SBT-11-5301, into the clinic in healthy volunteers later this year

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Hengrui Set For Biggest Biopharma IPO So Far This Year

 
• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

 
• By Mandy Jackson

Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

More from Business

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.